Muriel D. David

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 444 citations · Full text

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 422 citations · Full text

Idh1 Mutant Cancers, Somatic Point Mutations, Somatic Variant +14

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Michael Amatangelo, Lynn Quek, Alan H. Shih et al. · Blood · 2017 · 346 citations · Full text

Distinct Structural Features ofCaprin-1 Mediate Its Interaction with G3BP-1 and Its Induction of Phosphorylation of Eukaryotic Translation InitiationFactor 2<i>α</i>, Entry to Cytoplasmic Stress Granules, and Selective Interaction with a Subset of mRNAs

Samuel G. Solomon, Yaoxian Xu, Bin Wang et al. · Molecular and Cellular Biology · 2007 · 263 citations · Full text

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek, Muriel D. David, Alison Kennedy et al. · Nature Medicine · 2018 · 193 citations · Full text

Hematological Malignancy, Clonal Heterogeneity, Medicine +11